Journal of the National Cancer Institute · 2026
Evaluating the role of Medicaid expansion on survival in early-onset colorectal cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gawdi Rohin, Sjolander Elizabeth Nilsson, Lee Joon Sub, Whelan Richard L
Аннотация
BACKGROUND: The Affordable Care Act expanded Medicaid eligibility to states on staggered timelines, creating a natural experiment to assess health policy effects on colorectal cancer (CRC) outcomes.
METHODS: We conducted a retrospective quasi-experimental cohort study using the Surveillance, Epidemiology, and End Results database (2006-2019). Patients with CRC <65 years were included in primary analyses; an early-onset colorectal cancer (EOCRC) cohort aged <50 years was examined. States were classified by Medicaid expansion timing, and each expansion group was propensity score-matched against non-expansion controls. The primary analysis used pooled Bayesian difference-in-differences survival models with censoring at 36 months, with sensitivity analyses at 60 months and uncapped follow-up. Secondary Bayesian logistic models evaluated stage at diagnosis and receipt of surgical resection. Results are reported as hazard ratios (HR) or odds ratios (OR) with 95% credible intervals (CrI) and posterior probabilities of benefit.
RESULTS: In pooled analyses among patients younger than 65 years, Medicaid expansion was associated with reduced mortality (36-month HR = 0.86; 95% CrI = 0.81-0.92; P[HR < 1]>.999), with consistent findings across follow-up endpoints. Survival benefit was larger among patients with early-onset CRC (age <50 years). No consistent association was observed among Medicare-eligible patients aged ≥65. Medicaid expansion was not associated with population-level shifts in stage at diagnosis or increased surgical resection.
CONCLUSION: Medicaid expansion under the Affordable Care Act was associated with a high probability of improved CRC survival among non-Medicare-eligible adults, including patients with early-onset disease. Survival gains occurred without corresponding changes in stage or surgical treatment, suggesting benefits mediated through improved access, continuity, and delivery of cancer care.
METHODS: We conducted a retrospective quasi-experimental cohort study using the Surveillance, Epidemiology, and End Results database (2006-2019). Patients with CRC <65 years were included in primary analyses; an early-onset colorectal cancer (EOCRC) cohort aged <50 years was examined. States were classified by Medicaid expansion timing, and each expansion group was propensity score-matched against non-expansion controls. The primary analysis used pooled Bayesian difference-in-differences survival models with censoring at 36 months, with sensitivity analyses at 60 months and uncapped follow-up. Secondary Bayesian logistic models evaluated stage at diagnosis and receipt of surgical resection. Results are reported as hazard ratios (HR) or odds ratios (OR) with 95% credible intervals (CrI) and posterior probabilities of benefit.
RESULTS: In pooled analyses among patients younger than 65 years, Medicaid expansion was associated with reduced mortality (36-month HR = 0.86; 95% CrI = 0.81-0.92; P[HR < 1]>.999), with consistent findings across follow-up endpoints. Survival benefit was larger among patients with early-onset CRC (age <50 years). No consistent association was observed among Medicare-eligible patients aged ≥65. Medicaid expansion was not associated with population-level shifts in stage at diagnosis or increased surgical resection.
CONCLUSION: Medicaid expansion under the Affordable Care Act was associated with a high probability of improved CRC survival among non-Medicare-eligible adults, including patients with early-onset disease. Survival gains occurred without corresponding changes in stage or surgical treatment, suggesting benefits mediated through improved access, continuity, and delivery of cancer care.